Subscribe
shutterstock_2130367208_luca_perra
19 December 2023Big PharmaMarisa Woutersen

Pharma industry pushes back on Biden’s ‘dangerous’ plan

The Biden administration’s proposals target price gouging triggers resistance | The move, which includes the consideration of march-in rights for taxpayer-funded drugs, may ‘jeopardise collaborative partnerships and hinder innovation.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Biden takes aim at big pharma in controversial plan
12 December 2023   US government takes on price gouging in latest raft of proposals | IP attorney says the “unfortunate decision” will deter future public-private collaboration | Move prompts concern over government's future use of march-in rights.
Americas
Bernie Sanders blasts big pharma for ‘ripping off’ patients
8 February 2024   Senator criticises patent thickets and ‘monopolies’ ahead of senate hearing convened to interrogate CEOs | Sales of MSD’s blockbuster cancer treatment Keytruda rival McDonald’s annual revenue, says report.
article
Pharma body attacks ‘vague’ march-in rights plan
8 February 2024   PhRMA says controversial draft framework misinterprets the Bayh-Dole Act and could undo years of success | FTC unanimously supports the proposal.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

Big Pharma
Biden takes aim at big pharma in controversial plan
12 December 2023   US government takes on price gouging in latest raft of proposals | IP attorney says the “unfortunate decision” will deter future public-private collaboration | Move prompts concern over government's future use of march-in rights.
article
Pharma body attacks ‘vague’ march-in rights plan
8 February 2024   PhRMA says controversial draft framework misinterprets the Bayh-Dole Act and could undo years of success | FTC unanimously supports the proposal.
Americas
Bernie Sanders blasts big pharma for ‘ripping off’ patients
8 February 2024   Senator criticises patent thickets and ‘monopolies’ ahead of senate hearing convened to interrogate CEOs | Sales of MSD’s blockbuster cancer treatment Keytruda rival McDonald’s annual revenue, says report.

More on this story

Big Pharma
Biden takes aim at big pharma in controversial plan
12 December 2023   US government takes on price gouging in latest raft of proposals | IP attorney says the “unfortunate decision” will deter future public-private collaboration | Move prompts concern over government's future use of march-in rights.
article
Pharma body attacks ‘vague’ march-in rights plan
8 February 2024   PhRMA says controversial draft framework misinterprets the Bayh-Dole Act and could undo years of success | FTC unanimously supports the proposal.
Americas
Bernie Sanders blasts big pharma for ‘ripping off’ patients
8 February 2024   Senator criticises patent thickets and ‘monopolies’ ahead of senate hearing convened to interrogate CEOs | Sales of MSD’s blockbuster cancer treatment Keytruda rival McDonald’s annual revenue, says report.

More features

Sandoz lands reduced antitrust award of $70m
New president’s to-do list: Patent bills, non-competes, USPTO director?
Sanofi subsidiary fends off $450m trade secrets case
Regulatory expert joins White & Case
Teva faces $500m fine for antitrust breaches over MS drug
UK Budget: A missed opportunity?
Pfizer infringed haemophilia therapy patent, says court
Cooley adds ex-Gowling partner